Breast Cancer, the Genetic  QuickFix,  and the Jewish Community: Ethical, Legal, and Social Challenges by Rothenberg, Karen H.
HeinOnline -- 7 Health Matrix 97 1997
BREAST CANCER, THE GENETIC 
"QUICK FIX," AND THE JEWISH 
COMMUNITY 
ETHICAL, LEGAL, AND SOCIAL CHALLENGES 
Karen H. Rothenberg, J.D., M.P.A.t 
TABLE OF CONTENTS 
I. 
II. 
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . 98 
GENETIC TESTING IN CONTEXT: 
EMERGING THEMES . . . . . . . . . . . . . . . . . . . . 102 
A. Genetic Myopia, the Genetic "Quick-Fix," and 
the Genetic Underclass ................ . 
B. Genetic Accountability and Genetic Identity . . . 
III. ETHICAL AND LEGAL IMPLICATIONS OF 
INFORMED CONSENT .................. . 
IV. GENETIC INFORMATION AND 
HEALTH INSURANCE .................. . 
V. GENETIC INFORMATION AND THE 
WORKPLACE .......................... . 
VI. PRIVACY AND CONFIDENTIALITY OF 
102 
104 
105 
107 
113 
t Marjorie Cook Professor of Law and Director, Law and Health Care Program, 
University of Maryland School of Law; B.A., Princeton University, 1973; M.P.A., Woodrow 
Wilson School of Public and International Affairs, Princeton University, 1974; J.D., University of 
Virginia, 1979. This Anicle evolved from the author's presentation at the Workshop on Inherited 
Breast Cancer in Jewish Women: Ethical, Legal, and Social Implications, Case Western Reserve 
University, April26, 1996. In addition, parts of the Article are adapted from Genetic Information 
and Health Insurance: State Legislative Approaches, J. LAW, MED. & ETHICS 312 (1995) and 
Predictive Genetic Testing for Cancer: Ethical, Legal, Social and Public Policy Challenges, in 
ACCOMPLISHMENTS IN CANCER REsEARCH 1995, at 209 (General Motors Corp. ed., 1996). The 
author wishes to thank her colleagues at the National Cancer Institute and the National Center for 
Human Genome Research, National Institutes of Health, for their expertise and resources, the 
participants at the Workshop for the insights and questions, and especially Barbara Fuller, J.D. for 
her outstanding contribution to this Article. 
97 
HeinOnline -- 7 Health Matrix 98 1997
98 HEALTH MATRIX [Vol. 7:97 
GENETIC INFORMATION . . . . . . . . . . . . . . . . . 115 
VII. RIGHTS AND RESPONSIBILITIES WITHIN 
THE FAMILY . . . . . . . . . . . . . . . . . . . . . . . . . . 118 
VIII. CONCLUSION: UNANSWERED QUESTIONS 123 
I. INTRODUCTION 
Nearly one percent of over 850 DNA samples from Eastern 
European Jews contained a specific gene mutation that may 
predispose them to breast and ovarian cancer, according to 
study results published today in Nature Genetics. 1 
This finding offers the first evidence from a large study that an 
alteration in the gene, called breast cancer I (BRCAl), is pres-
ent at measurable levels not only in families at high risk for the 
disease, but in a specific group of the general population.2 
With the publication of today's results, the National Institutes 
of Health (NIH) also announced its plans to launch a series of 
clinical studies to evaluate cancer risk in Eastern European, or 
Ashkenazi, Jews bearing the mutation. The results of these 
studies will help determine whether BRCAl testing should be 
offered to the nation's six million Ashkenazi Jews as a part of 
their health care.3 
IT WAS TIDS NIH PRESS RELEASE dated September 
28, 1995, and the press conference that followed, that would 
first alert and alarm the Jewish community. The BRCAI gene 
had been isolated a year earlier and numerous unique mutations 
had been detected in the germline of individuals with breast 
and ovarian cancer.4 About five to ten percent of all breast 
1. Scientists Report New Lead in the Genetics of Breast Cancer, NIH NEWS (Nat') Inst of 
Health, U.S. Dept. of Health & Hum. Serv., Washington, D.C.), Sept 28, I 995, at I (citing Jeffrey 
P. Struewing et al., The Carrier Frequency of the BRCA1185delAG Mutation is Approximately 1 
Percent in AshkenaziJewish Individuals, II NATURE GENETICS 198, I98 (1995)). 
2. I d. at 1. 
3. /d. at 1. 
4. See Jeffrey P. Struewing et al., The Carrier Frequency of the BRCA1185delAG Muta-
tion is Approximately 1 Percent in Ashkenazi Jewish Individuals, I I NATURE GENETICS I98, 199 
(noting that data has been derived almost exclusively from families with a wide range of 
mutations ascertained on the basis of a high incidence of breast and ovarian cancer, and that it is 
HeinOnline -- 7 Health Matrix 99 1997
1997] ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS 99 
cancers appear to be inherited and a significant proportion were 
related to the BRCAl gene.5 In high-risk families, female car-
riers of BRCAl mutations were estimated to have an eighty-
five percent lifetime risk of breast cancer and a forty percent 
risk of ovarian cancer.6 Because current mutation detection is 
very difficult, it has not been feasible to analyze large numbers 
of samples, but the 185delAG mutation had been detected rela-
tively frequently.7 Of the ten published families with this mu-
tation, it was discovered that all were Ashkenazi Jews.8 Thus, 
this association between a specific mutation and a genetic 
subpopulation prompted the scientists to target the Jewish 
population for further genetics research on the prevalence of 
the BRCAl mutation.9 
A follow-up population study tested eight hundred fifty-
eight stored DNA samples taken from Ashkenazi individu-
als.10 These samples had originally been collected for Tay-
Sachs and Cystic Fibrosis screening in the United States and 
Israel, and thus, were not chosen for the presence of breast 
cancer or positive family history for cancer.11 All individual 
identifiers were removed from the samples prior to analysis.12 
Eight of the samples were carriers for the 185delAG, whereas 
none of the eight hundred fifteen samples in the control group 
(not selected for ethnic origin) tested positive. 13 Thus, about 
one percent (0.9%) of the Jewish samples carry this mutation, 
apparently derived from a common ancestor.14 This is a sur-
prisingly high frequency, making this mutation "potentially the 
possible that the penetrance will be lower in unselected patients). 
5. /d. 
6. /d. 
7. /d. 
8. /d. It was subsequently reported that over twenty Jewish families with breast or ovarian 
cancer had been identified with the 185de!AG. See Francis S. Collins, BRCA/ --Lots of Mutations, 
Lots of Dilemmas, 334 NEW ENG. J. MED. 186, 186 (1996) (presenting issues related to BRCA1 
testing including pros and cons of testing individuals). 
9. It has also been reported by U.S. and French researchers that at least 3 in 1,000 
Ashkenazi Jews might carry one particular alteration in BRCA2. Rita Rubin, Would I Gain by 
Being Tested? No, U.S. NEWS & WORLD REP., May 13, 1996, at 77. 
10. See Struewing et al., supra note 4, at 198 (explaining the methods and results of the 
genetic sample study). 
11. See id. 
12. See id. 
13. See id. 
14. See id. 
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most common serious single-gene disease yet identified in any 
population group."15 It is estimated that this rate of alteration 
is three16 to eighe7 times higher than all BRCA1 alterations 
combined in the general population. 
The NIH researchers conceded that "[w]hile the finding 
raises the possibility of testing, it does not provide any data on 
precise cancer risk."18 Scientists still do not know to what 
extent having the altered gene increases a woman's risk of de-
veloping breast or ovarian cancer. Nor do they know to what 
extent it might increase the risk for colon or prostate cancer in 
men. Thus, NIH scientists, with the support of Jewish commu-
nity leaders, conducted a follow-up study on blood samples of 
over five thousand men and women from the Ashkenazi Jewish 
population in the Washington, D.C. area. The purposes of the 
study were: "1) to learn how common the 185delAG alteration 
is, and 2) to see if people with this alteration have more rela-
tives with cancer."19 The study did not involve testing for can-
cer and study participants_did not receive test results. In addi-
tion to a blood sample, participants filled out a questionnaire 
about family history of cancer and information about ancestry. 
Jewish leaders actively encouraged people to participate and 
many synagogues and Jewish community centers served as 
sites for the study. "In history, Jews have bled for negative rea-
sons,"20 and this was an opportunity for Jews to give blood to 
help their people, said Rabbi Matthew Simon, the president of 
the UJA Federation of Greater Washington.21 Within less than 
two months, between February and April, 1996, NIH and the 
Jewish organizations had recruited over five thousand Jews in 
the Washington, D.C. area for participation in this study. 
15. Collins, supra note 8, at 186. 
16. See The 185de/AG Alteration in BRCAJ: What does this Mean for Jewish Women, 
FAcr SHEET (Nat'!. Inst of Health, U.S. Dep't of Health & Hum. Serv., Washington, D.C.), 
1995, at 5. 
17. See Collins, supra note 8, at 186. 
18. See Nat'! Inst. of Health, supra note I, at I (quoting Dr. Jeffrey Struewing, scientist 
with the National Cancer Institute and the National Center for Human Genome Research). 
19. Nat'! Inst. of Health, Familial Cancer and the BRCAJ Gene in the Jewish Community 
of Greater Washington (1996) (informed consent form from NIH research study) (on file with 
author). 
20. Doctors Launch New Jewish Cancer Test: Amid Fear and ConfUsion, Search Facts Be-
gins, FORWARD, Mar. I, 1996, at 5 [hereinafter Doctors Launch Nev.• Jewish Cancer Test]. 
21. Jd. 
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Even though the study results are yet to be reported, tar-
geting Jews for testing is growing in both the research commu-
nity and in the commercial market. Numerous studies are now 
in place to test Jewish women for the 185delAG in BRCAl 
mutation.22 For example, four thousand Ashkenazi women with 
recently diagnosed breast cancer are being recruited from seven 
metropolitan New York City hospitals. Participants in this 
study will receive results and will be followed for four 
years.23 Even though the essential research on precise cancer 
risks has not been completed, commercial laboratories are also 
targeting Jews for testing. The Genetics and In-Vitro Fertiliza-
tion (IVF) Institute in Fairfax, Virginia advertises on the 
Internet that it will offer population screening to Ashkenazi 
Jews for the 185delAG mutation, even though "[t]here are 
many questions . . . that still need to be answered in careful 
clinical studies."24 The Jewish Week, a popular Jewish news-
paper, suggests that if you want more information on the 
185delAG test, "have your doctor contact The Genetics and 
IVF Institute."25 Currently, the cost of the test is $295.26 The 
Genetics and IVF Institute also advertises that it will test for a 
few additional mutations in Jewish families, but cannot yet 
offer such testing to non-Jews, "since no other mutations have 
yet been identified that are specific for a particular ethnic or 
racial group.'m 
22. See generally Nancy J. Nelson, A Burst of Research Activity Follows BRCAJ Finding, 
88 J. NAT'L CANCER INST. 230, 230 (1996) (describing several genetic studies initiated in the 
aftennath of the discovery of the BRCAl gene). The Fox Chase Cancer Center in Philadelphia, 
Pa., was testing for the 185delAG deletion in several hundred Ashkenazi women, both affected 
and unaffected. ld. at 231. The Women's College Hospital in Toronto is testing for the 
185delAG deletion in 200 to 300 Jewish women with ovarian cancer. ld. The University of Utah, 
Salt Lake City and Memorial Sloan-Kettering Cancer Center in New York have tested for the 
185delAG deletion in young Jewish women with breast cancer or in families with one or two 
affected first-degree relatives. I d. 
23. ld. at 230-31. 
24. See Genetics & IVF Institute, Breast and/or Ovarian Cancer Risk in Jewish Women: 
Role of the 185delAG and other Mutations in the BRCAJ and BRCA2 Genes (visited Aug. 25, 
1996) (http://www.givf.com/brcal.html) (describing the role of mutations in the BRCA1 and 
BRCA2 genes and promoting genetic screening for Ashkenazi Jews as a specifically affected 
group). 
25. Diana Willensky, Optimism in Breast Cancer Fight, JEWISH WEEK, Mar. 8, 1996, at 45. 
26. See Ridgely Ochs, Genetic Findings on Breast Cancer/The Door's Open, Researchers 
Say, But the Landscape Remains Murky, NEWSDAY, May 14, 1996, at B23 (describing recent 
findings related to BRCA1 and options for testing). 
27. Genetics & IVF Institute, supra note 24. 
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Most recently, the Hartford Jewish Ledger began printing 
on a regular basis an advertisement entitled, "An Important 
Message-- Genetic Testing for Breast Cancer in Jewish Wom-
en," by Kenneth A. Kern, M.D.28 Dr. Kern first states that 
"[s]everal recent cancer studies have confirmed that Jewish 
women of Ashkenazi (Eastern European) heritage carry dam-
aged genes that lead to breast cancer more commonly than the 
non-Jewish population."29 Relying on numerous statistics he 
declares as fact "if you carry damaged breast cancer genes 
and you live long enough, you are almost guaranteed to de-
velop breast cancer."30 Dr. Kern then offers to provide genet-
ic testing "by a blood test"31 in his office. He concludes that 
"the decision to undergo testing requires thought, counseling, 
and courage.'m Obviously, the research agenda has fueled 
the marketing strategy for the commercialization of predictive 
genetic testing for breast cancer. 
IT. GENETIC TESTING IN CONTEXT: 
EMERGING THEMES 
A. Genetic Myopia, the Genetic "Quick-Fix," and the 
Genetic Underclass 
Before the ethical, legal, and social challenges embedded 
in predictive genetic testing for breast cancer in Jewish women 
can be addressed, it must first be placed more generally in the 
context of developing genetic technologies in our society. 
Three themes emerge which will be briefly explored: genetic 
myopia; genetic testing as a "quick fix"; and the genetic 
underclass. Genetic myopia is a condition that results from 
viewing everything from the perspective of genetics. As a 
result, genetic reductionism and genetic determinism develop in 
28. Kenneth A. Kern, An Important Message -- Genetic Testing for Breast Cancer in 
Jewish Women, HARTFORD JEWISH LEDGER, Nov. 22, 1996, at 13 (advertising that Dr. Kern spe-
cializes in "Diseases of the Breast and Tumor Surgery'~. 
29. !d. 
30. !d. 
31. !d. 
32. !d. (emphasis added). 
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our society.33 Genetic reductionism results when all traits, 
health problems, and behaviors become attributable to genes 
and no attention is paid to other potential factors. Thus, if a 
gene for cancer is found in an individual, other factors, such as 
environmental toxins, lifestyle, and diet, will be dismissed as 
not contributing to the development of the disorder. In a relat-
ed way, genetic determinism results when an individual be-
lieves her future is defmed and predicted by genetic makeup 
and cannot be changed. People may not be motivated to adopt 
a healthy lifestyle if they believe that their fate is predeter-
mined genetically and therefore, that they cannot prevent dis-
ease by reducing other risk factors such as smoking cigarettes. 
Such attitudes may have significant negative implications for 
public health and prevention messages. Genetic myopia may, in 
fact, seriously undermine cancer surveillance and prevention 
strategies aimed at the population at large. 
The genetic "quick fix" theme views genetic testing as an 
end in and of itself, rather than as a means toward an end that 
is yet to be defmed. By trying to perfect the predictive test, 
have we failed to concurrently think through what to do once 
the test result is available? What is the value of the informa-
tion, its benefits and risks to individuals and their families, its 
impact on health behavior, and the role of providers in advis-
ing about the implications and limitations of test results? 
The "genetic underclass" theme describes a future popula-
tion unable to gain access to genetic testing in the United 
States. At present, we live in a society where over forty million 
people have no health insurance and limited or no access to 
our health care system.34 Without access to health care, it is 
unlikely that these individuals would have access to genetic 
testing or related services. How will resources be allocated to 
33. See, e.g., Abby Lippman, Prenatal Genetic Testing and Screening: Constructing Needs 
and Reinforcing Inequities, 17 AM. J. L. & MEn. 15, 17-18 (1991) (exploring the consequences of 
prenatal genetic testing and screening on women and their health care needs); Dorothy Nelkin, 
The Grandiose Claims of Geneticists, CHRON. HIGHER Eouc., Mar. 3, 1991, at Bl (suggesting 
that the rhetoric used by geneticists could foster genetic determinism and be used to justify 
discrimination). 
34. See Sources of Health Insurance and Characteristics of the Uninsured: Analysis of the 
March 1994 Current Population Survey, SPECIAL REPORT AND ISSUE BRIEF No. 158 (Employee 
Benefit Research Institute, Washington, D.C.), Feb. 1995, at 1, 4 (providing summary data on the 
insured and uninsured as weJJ as discussing changes in health protection). 
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make sure that in the future, the economic underclass does not 
also become the genetic underclass? 
B. Genetic Accountability and Genetic Identity 
Two additional themes emerge in the context of testing for 
inherited breast cancer in the Jewish community: genetic ac-
countability and genetic identity. These themes are not unique 
to Jewish women, but provide a useful paradigm for further 
analysis and for placing genetic testing in context. Historically, 
pregnant women have been the main targets of genetic testing, 
and mothers serve as the primary caretakers of those born with 
genetic disorders. Genetic accountability results when women 
are deemed responsible for seeking genetic information.35 
Women may believe they have a duty to give birth to the per-
fect baby free of genetic abnormalities. The expansion of ge-
netic testing may give the impression that we can and should 
take complete control and responsibility for the results of birth. 
Although many pregnant women may feel this sense of genetic 
accountability, certain ethnic groups, including Jewish women, 
have historically been targeted for testing. Historically, Jewish 
women have accepted that it is their responsibility to be tested 
for their carrier status for Tay-Sachs, a "Jewish" genetic dis-
ease.36 Indeed, the Orthodox Jewish community has estab-
lished a counseling and testing program for couples prior to 
being matched for marriage, 37 called Dor Y eshorim, that pro-
motes carrier testing for Tay-Sachs and a few other genetic 
disorders more common among Jews. Testing, however, is only 
done for recessive genetic disorders which require two carriers 
for there to be a risk to future offspring. Dor Yeshorim's edu-
cational materials include a reprint of a letter from a mother 
who did not have her daughter tested before the daughter mar-
35. See generally R. Alta Charo & Karen H. Rothenberg, "The Good Mother": The Limits 
of Reproductive Accountability and Genetic Choice, in WOMEN AND PRENATAL TEsTING: FACING 
THE CHALLENGES OF GENETIC TECHNOLOGY 105 (Karen H. Rothenberg & Elizabeth J. Thomson 
eds., 1994) (discussing the issues surrounding reproductive genetic testing and responses to the 
increased responsibilities it may create). 
36. See generally id. 
37. See COMMISSION FOR PREVENTION OF JEWISH GENETIC DISEASES, DoR YESHORIM, 
AVOID A TERRIBLE TRAGEDY FOR YOU AND YOUR CHILDREN! (1996). 
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ried. The daughter subsequently gave birth to a child with Tay-
Sachs.38 The mother writes: "I am guilty, no one but I am 
guilty of their present tragic state."39 Thus, genetic account-
ability in both the preconceptual and the prenatal context has 
been part of the Jewish culture for many years. 
Genetic accountability and genetic identity are now ex-
panding beyond prenatal testing. Jewish women may perceive a 
"social obligation to do anything they [can] to advance"40 re-
search on BRCAl testing. Accordingly, at least one researcher 
has warned that "those obtaining consent for Jewish women 
[for BRCAl testing] should be aware of the 'slippery slope' 
from perceived social responsibility to coercion."41 Further-
more, Jewish women feel particularly responsible for seeking 
information about genetic predisposition to breast cancer, in 
part for the "sake of one's children."42 As noted earlier, much 
of the attention in research, the commercial market place, and 
the media over the last year has been on the "Jewish genes" 
for breast cancer. Newspaper headlines sum it all up: "Doctors 
Launch New Jewish Cancer Test"43 and "Doc Wants New 
Study of Jewish Cancer Gene."44 For Jews, a genetic identity 
to familial cancer is being legitimized by our drive for the 
genetic "quick fix." 
ill. ETIDCAL AND LEGAL IMPLICATIONS Of 
INFORMED CONSENT 
With these themes in context, the ethical and legal issues 
can become more focused. The first issue, with both ethical 
and legal implications, is informed consent. The informed 
consent model for genetic (and HIV) testing has altered the 
traditional paradigm. Rather than focusing on the medical risks 
38. A Letter Received by Dor Y eshorim with the·Request to Publicize it to the Community 
(Dor Yeshorim trans.) (Dor Yeshorim, Washington, D.C.) 1995. 
39. Id. 
40. Gail Geller et al., Informed Consent and BRCAJ Testing, 11 NATURE GENETICS 364, 
364 (1995). 
41. ld. 
42. Id. 
43. Doctors Launch New Jewish Cancer Test, supra note 20, at 5. 
44. Doc Wants New Study of Jewish Cancer Gene: Is Screening Warranted?, FORWARD, 
Feb. 9, 1996, at 6 [hereinafter Doc Wants New Study of Jewish Cancer Gene) (calling for a study 
to see whether screening and prevention are necessary). 
HeinOnline -- 7 Health Matrix 106 1997
106 HEALTH MATRIX [Vol. 7:97 
associated with the procedure, which are minimal, the emphasis 
is on disclosure of the psychological and societal risks for the 
individual and family receiving the information.45 It is impor-
tant to note, however, that it is very difficult to have a mean-
ingful informed consent process when we still know so very 
little about the relative risks and benefits of genetic testing. 
A number of assumptions have been made about the bene-
fits of predictive testing and the value of predictive informa-
tion. It has been argued that test results will relieve uncertain-
ty; promote early detection, surveillance, prevention, and inter-
vention strategies; enable us to better plan for the future; influ-
ence reproductive decision making; and give us information to 
share with blood relatives (particularly children), so that they 
can better assess their risk for cancer. 
On the other hand, assumptions are made about the risks 
as well. These are not the traditional risks associated with an 
invasive, medical intervention. Rather, as noted earlier, they are 
social and psychological risks that typically have not been the 
major focus of the informed consent process. It has been ar-
gued that genetic information will increase anxiety; change 
self-image; alter family relationships; create social and group 
stigma; impact on privacy and confidentiality; and result in 
both insurance and employment discrimination. 
In fact, we must question the assumptions about both 
benefits and risks. The reality is that we have very little data. 
First of all, the value of this predictive information is unknown 
and it will remain unknown for the near future. Further, it is 
important to emphasize that whereas genetic information may 
be predictive, it is not, in and of itself, a definitive diagnosis. 
Additionally, it is difficult for individuals to evaluate both 
predictive information and relative risks and how those relate 
within the context of their lives.46 Finally, these predictive 
tests are not perfect and may never be for all population 
groups. How can such limitations be translated, if at all, for the 
45. See generally OFFICE FOR I'ROTEC110N FROM REsEARCH RISKS, U.S. DEPT. OF HEALTH 
& HUM. SERV., PROTECfiNG HUMAN REsEARCH SUBJECTS, INSTITUTIONAL REVIEW BOARD 
GUIDEBOOK 5-42 to 5-63 (I 993) (addressing ethical issues raised by human genetic research). 
46. See Elizabeth J. Thomson, Communicating Complex Genetic Information, in GENES 
AND HUMAN SELF-KNOWLEDGE 172 (R.F. Weir et al. eds., 1994). 
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individual not trained in genetics or risk assessment? How 
good, in fact, does the genetic information have to be in order 
to benefit individuals as members of society? In light of the 
above, it becomes critical for the health care provider to be 
skilled in risk assessment in order to determine who best can 
potentially benefit from genetic testing. Thus, the evolving 
standard of care should not be focused on the provider's duty 
to offer testing, per se, but rather on the quality of risk assess-
ment and the appropriateness of testing. 
Accordingly, we must also question the assumptions made. 
about predictive testing and its potential for a positive impact 
on cancer surveillance and prevention strategies. What, in fact, 
do we currently know about baseline health promotion and 
disease prevention behaviors? Based on what we know about 
cancer prevention and interventions, what assumptions are 
reasonable to make with respect to adherence, change of be-
havior, and access to these strategies in our current health care 
system? Furthermore, what should people with a positive test 
be advised? Should they be told to obtain mammograms more 
often or less often? Should women with BRCAI mutations be 
offered chemoprevention and/or prophylactic mastectomies as 
prevention strategies?47 Should men with mutations be offered 
prophylactic prostatectomy? How can we counsel about the 
benefits and risks of surgical options without any long-term 
data on the impact of such interventions? We need to formulate 
a risk/benefit analysis to determine whether the benefits of 
predictive testing for cancer outweigh the risks with respect to 
both medical and psychological well-being. 
IV. GENETIC INFORMATION AND HEALTH 
INSURANCE 
One societal risk at issue is the discrimination that may 
result in the health insurance setting.48 Researchers report that 
47. See Struewing et al., supra note 4, at 198. See also Yoshio Miki et al., A Strong 
Candidate for the Breast and Ovarian Cancer Susceptibiliry Gene BRCAJ, 266 SCIENCE 66, 66 
(1994) (discussing the identification of the BRCA1 gene and how it will facilitate early diagnosis 
of breast and ovarian cancer susceptibility). 
48. See Karen H. Rothenberg, Genetic Information and Health Insurance: State Legislative 
Approaches, 23 J. LAw MED. & ETHICS 312, 312 (1995) (detailing state approaches to the 
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individuals considering enrollment in clinical genetic studies 
fear that if genetic information is disclosed to third parties, 
individuals and their families may face discrimination. 49 Until 
a few years ago, it was rare for legislation to address genetic 
information in the health insurance context. In the 1970s, North 
Carolina and Florida passed legislation prohibiting health insur-
ers from refusing to issue insurance or charging higher premi-
ums based on the sickle cell trait. In 1986, Maryland passed 
legislation (since amended) that covered a number of traits 
including Tay-Sachs, although insurers could continue to use 
genetic information to discriminate if there was "actuarial 
justification. "50 
With the advent of the Human Genome Project, a new 
generation of state legislation began to evolve with the pas-
sage, in 1991, of a Wisconsin law prohibiting health insurers 
from: 
• requiring or requesting an individual or a member of the 
individual's family to obtain a genetic test; 
• requiring or requesting directly or indirectly the results of a 
genetic test; 
• conditioning the provision of insurance coverage or benefits 
on genetic testing; or 
• considering genetic testing in the determination of rates. 51 
This approach attempts to integrate protection against 
discrimination in insurance practices, coverage, benefits, and 
rates with some privacy protection for the individual and 
his/her family. Similar approaches have been incorporated to 
varying degrees in recent legislation passed in Califomia/2 
problem of discrimination by insurance carriers based on genetic information); Kathy L. Hudson 
et al., Genetic Discrimination and Health Insurance: An Urgent Need for Refonn, 270 SCIENCE 
391, 391 (1995) (focusing on proposed reforms to protect consumers from health insurance 
discrimination based on genetic information). See generally Ruth R. Faden & Nancy E. Kass, 
Genetic Screening Technology: Ethical Issues in Access to Tests by Employers and Health 
Insurance Companies, J. Soc. ISSUES, 1993, at 75, 83; Paul R. Billings et al., Discrimination as a 
Consequence of Genetic Testing, 50 AM. J. HUM. GENETICS 476,476 (1992). 
49. See Nat'! lnst. of Health, NIH-Funded Cancer Genetics Studies Consortium Meeting, 
Nov. 2, 1995. 
50. See Rothenberg, supra note 48, at 313. 
51. WIS. STAT. ANN.§ 631.89(2)(a)-(d) (1994). 
52. CAL. INS. CODE§§ 10123.2, 10123.3, 10123.31, 10123.35, 10140, 10140.1,1 0140.5, 
10147, 10148, 10149, 10149.1, 11512.95, 11512.96, 11512.965 (Deering 1996); CAL. HEALTH & 
SAFETY CODE§ 1374.7, 1374.9 (West 1994 & West 1995); S.B. 1740, 1995-96 Reg. Sess. (Cal. 
1996) (enacted). 
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Colorado,S3 Georgia,54 Maryland,55 Minnesota/6 New 
Hampshire,57 Ohio,58 Oregon,59 Virginia,60 and New Jer-
sey.61 Just within the last year, more than a dozen state leg-
islatures have considered bills addressing genetic discrimination 
in health insurance. 62 
The development of public policy to address genetic infor-
mation and health insurance must be analyzed in the context of 
a complex and inadequate health insurance system, the uncer-
tainty about the future scope and impact of genetic testing and 
the political realities of a pluralistic society. The current patch-
work of state legislation does not provide a comprehensive 
solution to genetic discrimination and health insurance. State 
laws focus narrowly on genetic tests, rather than more broadly 
on genetic information generated by family history, physical 
examination, or the medical record. Although insurers are 
prohibited from using the results of a chemical test of DNA, or 
the protein product of a gene, they can still use other pheno-
type indicators, patterns of inheritance of genetic characteris-
tics, or requests for genetic testing as the basis for discrimina-
tion.63 Thus, "[m]eaningful protection against genetic discrimi-
nation requires that insurers be prohibited from using all infor-
mation about genes, gene products, or inherited characteristics 
to deny or limit health insurance coverage."64 
Further, the federal Employee Retirement Income Security 
Act (ERISA) exempts self-funded plans from state insurance 
53. CoLO. REv. STAT. § 10-3-1104.7 (1996). 
54. GA. CODE ANN. § 33-54-1-4 (1996). 
55. Mo. ANN. CODE Art. 48a, § 223(a)(3) (1996). 
56. MINN. STAT.§ 72A.l39(3) (1995). 
57. N.H. REV. STAT. ANN.§ 141-H:4 (1995). 
58. Omo REV. CODE ANN. §§ 1742.42, 1742.43, 3901.49, 3901.491, 3901.50, 3901.501 
(Anderson 1996). 
59. S.B. 276, 68th Or. Leg. Assoc., Reg. Sess. (1995)(enacled). 
60. VA. CODE ANN. § 38.2-508.4 (Michie 1996). 
61. S.B. 695 & 854, 207th Leg., 1st Ann. Sess. (N.J. 1996) (enacted). 
62. See, e.g., H.B. 5705, 1996 Gen. Assembly Reg. Sess. (Conn. 1996) (prohibiting dis-
crimination based on an individual's genetic information in both employment and insurance 
conlexts); H.B. 1200, 109th Leg., 2d Reg. Sess. (Ind. 1996) (prohibiting health insurers from 
discriminating on the basis of genetic information); H.B. 2943, 89th Gen. Assembly (Ill. 1996) 
(amending various stale acts to prohibit the use of DNA information as a basis for certain in-
surability decisions). 
63. See Hudson et al., supra note 48, at 392. 
64. ld. 
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laws. Nationwide, more than one-third of the non-elderly in-
sured obtain health insurance through self-funded plans.65 This 
percentage is expected to increase as more and more employers 
use self-funded plans to provide health insurance benefits in 
the future. This Act preempts state law and therefore prevents 
a statewide approach to regulating the use of genetic informa-
tion by all plans providing health benefits. 66 
With these policy considerations in mind, the following 
recommendations were developed by the Working Group on 
Ethical, Legal, and Social Implications of the Human Genome 
Project (ELSI)67 and the National Action Plan on Breast Can-
cer (NAPBC)68 for both state and federal policymakers to pro-
tect against genetic discrimination:69 
I. Insurance providers should be prohibited from using genetic 
information, or an individual's request for genetic services, to 
deny or limit any coverage or establish eligibility, continuation, 
enrollment, or contribution requirements. 
2. Insurance providers should be prohibited from establishing 
differential rates or premium payments based on genetic infor-
mation or an individual's request for genetic services. 
3. Insurance providers should be prohibited from requesting or 
requiring collection or disclosure of genetic information. 
4. Insurance providers and other holders of genetic information 
should be prohibited from releasing genetic information without 
prior written authorization of the individual. Written authoriza-
tion should be required for each disclosure and include to 
whom the disclosure would be made.70 
The recommendations further provide that genetic infor-
mation be defmed as "information about genes, gene products, 
or inherited characteristics that may derive from the individual 
65. Id. 
66. /d. 
67. The NIH-DOE ELSI Working Group has a "broad and diverse membership including 
genome scientists; medical geneticists; experts in law, ethics, and philosophy; and consumers, to 
explore and propose options for the development of sound professional and public policies related 
to human genome research and its applications." Hudson et al., supra note 48, at 392-93. 
68. The National Action Plan on Breast Cancer (NAPBC) is a "public-private partnership 
designed to eradicate breast cancer as a threat to the lives of American women"; and NAPBC "has 
identified genetic discrimination in health insurance as a high priority." /d. at 393. 
69. These recommendations have been endorsed by the National Advisory Council on 
Human Genome Research (NACHGR). /d. 
70. /d. 
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or a family member."71 Insurance provider is defined as "an 
insurance company, employer, or any other entity providing a 
plan of health insurance or health benefits including group and 
individual health plans whether fully insured or self-funded."72 
Based in part on the interest generated by these recom-
mendations and a growing awareness of the issues, particularly 
among the breast cancer community and women's health advo-
cates, Congress has begun to take notice. The NAPBC/ELSI 
recommendations have been incorporated in proposed legisla-
tion introduced by Representative Louise M. Slaughtee3 and 
Senators Diane Feinstein,74 Connie Mack,75 and Olympia J. 
Snowe.76 Further, Senators Mark D. Hatfield77 and Peter V. 
Domenici78 and Representatives Clifford B. Stearns79 and Jo-
seph P. Kennedy80 have also introduced bills addressing ge-
netic discrimination in insurance and employment. Although 
none of these genetic-specific proposals have passed, they have 
influenced other health insurance legislation. The recently 
enacted Health Insurance Portability and Accountability Act of 
199681 specifically prohibits a group health insurance plan from 
using "genetic information" to establish rules for eligibility or 
continued eligibility. It also provides that genetic information 
shall not be treated as a preexisting condition "in the absence 
71. /d. 
72. /d. Furthennore, legislation should provide enforcement mechanisms, including civil 
and criminal liability to assure that insurance entities comply with these provisions. For example, 
as noted earlier, California provides that negligent and willful disclosure of genetic test results 
without authorization is subject to civil and criminal liability. CAL. INSUR. CODE §§ 10123.31, 
10140.1, 10149.1, 11512.96 (Deering 1996). 
73. H.R. 2748, 104th Cong. (proposing a bill entitled "Genetic lnfonnation Nondiscrimi-
nation in Health Insurance Act of 1995"). 
74. S. 1600, 104th Cong. (proposing a bill entitled the "Genetic Fairness Act of 1996"). 
75. ld. 
76. S. 1694, 104th Cong. (proposing a bill entitled the "Genetic lnfonnation Nondis-
crimination in Health Insurance Act of 1996"). 
77. SeeS. 1416, 104th Cong. (1995) (proposing a bill entitled the "Genetic Privacy and 
Nondiscrimination Act of 1996"). 
78. See S. 1898, 104th Cong. (1996) (proposing a bill entitled "Genetic Privacy and 
Nondiscrimination Act of 1996"). 
79. See H.R. 2690, 104th Cong. (1995) (proposing a bill entitled "Genetic Privacy and 
Nondiscrimination Act of 1995). 
80. See H.R. 3477, 104th Cong. (1996) (proposing an amendment to the Fair Labor Stan-
dards Act of 1938 which would restrict employers in obtaining, disclosing, and using genetic 
infonnation). 
81. See 104 Pub. L. No. 104-191, § 701, 110 Stat. 1936 (1996). 
HeinOnline -- 7 Health Matrix 112 1997
112 HEALTH MATRIX [Vol. 7:97 
of a diagnosis of the condition related to such infonnation."82 
Thus, a healthy woman who tests positive for a BRCAl muta-
tion would not be deemed to have a pre-existing condition 
related to breast cancer and this genetic infonnation could not 
be used in the detennination of eligibility for a group insurance 
plan, including self-funded plans. This is a significant first step 
in the evolution of federal legislation. Genetic infonnation, 
although not defined in the legislation, is recognized broadly as 
a "health-status-related factor" in need of specific protection.83 
Of course, this incremental approach to health care refonn 
does not provide the comprehensive protection outlined in the 
NAPBC/ELSI recommendations. It does not prohibit insurers 
from requiring or requesting genetic testing or requiring or 
requesting the results of genetic testing. Thus, the burden is on 
the individual to prove that the insurer used genetic infonna-
tion to deny coverage or affect the tenns and conditions of 
insurance. It does not require insurers to obtain authorization 
before disclosing genetic infonnation. Nor does it prevent a 
plan from increasing rates, excluding all coverage for a particu-
lar condition, or imposing lifetime caps on all benefits or on 
specific benefits.84 Such applicable tenns of a plan may have 
a disparate impact on individual enrollees and may adversely 
affect "individuals with serious illnesses."85 This fonn of dis-
crimination against women with breast cancer and/or a genetic 
predisposition to breast cancer, for example, would be pennit-
ted as long as plan characteristics are not "directed at individu-
al sick employees or dependents."86 Absent other contractual 
and legal protections, plans could specifically exclude, for 
example, prophylactic surgery. Of course, insurers might also 
argue that surgery was not medically necessary, was experi-
mental, and/or was not a covered benefit since the insured had 
only a predisposition to disease, but did not need treatment for 
cancer.87 
82. !d. § 70l(b)(l)(B). 
83. !d. 
84. See H.R. REP. No. 104-736, at 406 (1996) (noting that a plan may impose restrictions 
on coverage of conditions and benefits). 
85. !d. at 406. 
86. /d. at 406-07. 
87. See generally Katskee v. Blue Cross/Blue Shield, 515 N.W.2d 645 (Neb. 1994). 
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The Act provides even less protection for those not in 
group plans and provides no coverage for the uninsured. Thus, 
even if the uninsured had access to genetic testing, the risk of 
future insurance discrimination would be a reality. In addition, 
the uninsured would not benefit from genetic information if 
they could not afford to pay for the related prevention and 
intervention strategies, including more frequent mammograms 
and surgical interventions. 
V. GENETIC INFORMATION AND THE 
WORKPLACE 
Genetic information in the workplace also poses societal 
risks that impact on employment possibilities, health insurance, 
and privacy. Following a conditional offer of employment, 
employers can require a pre-employment medical exam which 
may include a physical examination and blood tests (including 
genetic tests). They may also require a general medical release 
of an individual's medical records. Courts have held that em-
ployers have a legitimate interest in the mental and physical 
condition of their employees if the conditions impact on one's 
ability to perform the job, or are otherwise job-related.88 An 
employer does not have to hire an employee who refuses to 
provide a general medical release. 89 Although an employer is 
prohibited from discriminating based on a disability, it is diffi-
cult for the individual to prove that she did not get a job or 
promotion, for example, based on her disability or other genet-
ic information.90 There is no specific prohibition on the 
employer's access to genetic information.91 
"Insured's breast-ovarian carcinoma syndrome was 'illness,' defined as 'bodily disorder' or 
'disease,' within meaning of health insurance policy, notwithstanding insurer's contention that 
syndrome was merely predisposition to cancer," and as such, prophylactic surgery for removal of 
ovaries was covered. /d. at 645, 652. 
88. See Mark A. Rothstein, Genetic Discrimination in Employment and the Americans with 
Disabilities Act, 29 Hous. L. REv. 23, 38, 52-68 (1992) (noting that the only exception to the 
ADA's prohibition on preemployment inquiries is that an employer may inquire into the 
applicant's ability to perform job-related functions). · 
89. I d. at 63-64. 
90. See id. at 52-68 (explaining the problems employees face when employers have access 
to employee medical and genetic information). 
91. See id. at 62-68 (describing ways in which the ADA allows employers to gain access to 
their employee's genetic information). 
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Employment opportunities and health insurance coverage 
are clearly intertwined. The employer has a business interest in 
hiring a healthy work force to limit health insurance claims. At 
present, employers offering self-funded plans can alter benefits 
to reduce or eliminate coverage for specific conditions or pro-
cedures. Although they cannot directly discriminate against an 
individual, they could decide, for example, not to cover partic-
ular procedures that may affect certain groups of people more 
than others. Since many employers directly review health in-
surance claims, as a practical matter, there is no assurance of 
medical privacy in the workplace. 
In order to protect against genetic discrimination in the 
workplace, in 1995, the U.S. Equal Employment Opportunity 
Commission issued a guidance in its compliance manual on the 
defmition of disability: the Americans with Disabilities Act 
(ADA) would protect individuals subjected to discrimination on 
the "basis of genetic information relating to illness, disease or 
other disorders."92 To further clarify their position, they cite 
as an example an individual with a positive predictive genetic 
test for colon cancer as being subject to protection under the 
ADA. However, this provision may not cover carriers of reces-
sive or X-linked disorders. To date, there have been no genetic 
discrimination complaints filed with the EEOC and the guide-
lines have yet to be tested in court. There is no federal law that 
specifically addresses the use, misuse, and access to genetic 
information in the workplace, although a number of proposals 
have recently been introduced.93 
Over the last few years, a number of states, including 
Wisconsin,94 Rhode Island,95 Iowa,96 New Y ork,97 New 
Hampshire,98 Oregon,99 and New Jersey100 have passed 
92. 2 EQUAL EMPLOYMENT OPPORTUNITY COMM'N, COMPLIANCE MANUAL, § 902, Order 
915.002, 902-45 (1995). 
93. See S. 1416, 104th Cong. (1995) (prohibiting discrimination by employers based on 
genetic information); H.R. 2690, 104th Cong. (1995) (proposing the protection of genetic 
information in the workplace); S. 1898, 104th Cong. § 301 (1996) (regulating the use of genetic 
information by employers); H.R. 3477, 104th Cong. (1996) (limiting the use of genetic 
information in determining preexisting conditions). 
94. See WIS. STAT. ANN.§ 111.372 (West 1996). 
95. See R.I. GEN. LAWS§ 28-6.7-1 (1995). 
96. See IOWA CODE ANN.§ 729.6 (West 1996). 
97. See A.B. 7839, 219th Gen. Assembly, 2d Reg. Sess. (N.Y. 1996) (enacted). 
98. See N.H. REV. STAT. ANN.§ 141-H:3 (1995). 
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legislation that, to varying degrees, prohibits genetic testing as 
a condition of employment; prohibits genetic testing without 
informed consent; prohibits the use of genetic test results to 
affect the terms, conditions, and privileges of employment; and 
prohibits payments of benefits to employees in return for tak-
ing a genetic test. As with most state legislation addressing 
health insurance and genetic discrimination, these laws also 
tend to focus narrowly on the genetic test. 101 These laws do 
not prohibit employers from requiring a general medical re-
lease. At least one state law appears to allow for genetic test-
ing without informed consent where it is shown to be directly 
related to the occupational environment.102 Since most em-
ployers will continue to have access to genetic information, the 
burden will be on the employee to prove that the employer 
used genetic information to discriminate in the workplace. 
VI. PRIVACY AND CONFIDENTIALITY OF 
GENETIC INFORMATION 
The privacy and confidentiality of genetic information is 
at issue in a number of contexts. Once again, there is no feder-
al law that specifically addresses genetic privacy and confiden-
tiality. There is currently a patchwork of legislative sources 
that addresses, to varying degrees, genetic privacy and confi-
dentiality. These include medical records confidentiality stat-
utes, public health data bases and registries, public health ge-
netic programs, research regulations, DNA databanks, and anti-
discrimination statutes. Most of these statutes provide for ex-
ceptions to confidentiality protections for criminal investiga-
tions, parentage, and adoption. 103 
Recently enacted state laws to prevent genetic discrimina-
99. See OR. REv. STAT.§ 659.036 (1995). 
100. See S.B. 695, 207th Leg., 1st Ann. Sess. (NJ. 1996) (enacted). This is a comprehensive 
slatute that includes provisions for employment, housing, banking, privacy, health, life, and 
disability insurance. !d. 
101. The recently enacted New Jersey slatute, in fact, does provide broader protection 
against the use of genetic information.ld. 
102. See, e.g., A.B. 7839, 219th Gen. Assembly, 2d. Reg. Sess. § 5 (N.Y. 1996) (enacted). 
103. See Lawrence 0. Gostin, Genetic Privacy, 23 J. LAW, MED. & ETHICS 320,326 (1995) 
(discussing the genetic information infrastructure and how the privacy of genetic information is 
addressed in the scientific community and through slate slatutes). 
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tion in health insurance integrate some strong privacy protec-
tion.104 As noted earlier, the Wisconsin law established that 
insurers may not "require or request directly or indirectly any 
individual to reveal whether the individual or a member of the 
individual's family has obtained a genetic test or what the 
results of the test, if obtained by the individual or a member of 
the individual's family, were."105 Many of the other state 
laws and pending bills have· also adopted this provision.106 
Ironically, a recent Wisconsin bill that would have expanded 
the definition of genetic test, deleted this provision.107 Propo-
nents of the bill believed that as long as state law prohibits the 
use of genetic information in the underwriting process, there 
may be legitimate reasons for health insurers to otherwise 
require or request genetic information.108 For example, they 
argued that health maintenance organizations, which are both 
insurers and health care providers, may need this information 
to treat the patient and insurers may need access to this infor-
mation to verify claims. 109 
Other states have further expanded on protecting the dis-
closure of genetic information. California, for example, prohib-
its disclosure of genetic test results to any third party without 
written authorization.110 Written authorization is required for 
each separate disclosure of genetic test results and shall specify 
the person or entity to whom the disclosure will be made. 
Negligent and willful disclosure without authorization are sub-
ject to both civil and criminal liability. 111 Colorado specif-
ically provides that information obtained from genetic testing 
104. See Rothenberg, supra note 48, at 3I4-I7. 
105. WJSC. STAT. ANN.§ 631.89(2)(b) (West I996). 
I 06. See Rothenberg, supra note 48, at 3 I 4- I 6. 
107. A.B. 227, 92d Leg., Reg. Sess. § 10 (Wis. I995) (amending existing Wisconsin law to 
allow insurers to require or request that an individual or an individual's family member obtain a 
genetic test or reveal whether such test has been obtained and the results). 
I08. See SPECIAL COMM. ON GENETIC & MED. INFO., WIS. JOINT LEGISLATIVE COUNCIL, 
LEGISLATION ON GENETIC & MED.INFO., A, B,93-I9 (I994) (discussing Assembly Billi265 and 
its listing of circumstances under which patient health care records can be released upon request 
without informed consent, including release to a health care provider rendering assistance to the 
patient). 
I09. /d. 
IIO. CAL. INS. CODE§ IOI49.1 (Deering I996). 
Ill. Id. 
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shall be "confidential and privileged,"112 and Oregon and 
Georgia establish that genetic information is the "property of 
the individual."113 Nevertheless, Oregon and Georgia both 
provide, as do a number of the other states, for specific excep-
tions in which written authorization is not required for disclo-
sure (i.e., paternity, criminal proceedings, health department 
protocols). Even when these statutes require informed consent 
prior to genetic testing, they do not address whether the in-
formed consent process will incorporate a warning that the test 
results may be disclosed without authorization under certain 
circumstances. 
Additionally, a Florida law passed in 1992 permits DNA 
analysis to be used in criminal prosecutions, other criminal 
matters, and paternity determinations without informed con-
sent.114 Except in these circumstances, the statute declares 
that the test results are the exclusive property of the person 
tested, are confidential, and may not be disclosed without con-
sent.115 Nevertheless, the statute does not prohibit the use of 
genetic information in determining health insurance coverage 
and benefits. If DNA test results are used in any decision to 
grant or deny insurance, the individual must be notified and the 
analysis must be repeated to verify its accuracy. 
Some statutes address privacy issues created by the access 
to shared insurance databases. The Wisconsin116 and New 
Hampshire117 laws provide that insurers writing life and dis-
ability income insurance, in addition to health insurance, can-
not use genetic test information when underwriting their health 
insurance policies. In Minnesota, where a life insurance compa-
ny may require a genetic test, the statute provides that written 
informed consent must include information on the uses and 
limitations of the test, as well as the individual's right to confi-
dential treatment of the information. 118 It is worth noting that 
112. COLO. REV. STAT.§ 10-3-1104.7(3)(a) (1996). 
113. S.B. 276, 68th Or. Leg. Ass., Reg. Sess. (1995) (enacted); GA. CODE ANN.§ 33-54-1(1) 
(1996). 
114. FLA. STAT. ANN.§ 760.40(2)(a) (West 1995). 
115. /d. 
116. WISC. STAT. ANN. 631.89(3)(b) (West 1996). 
117. N.H. REV. STAT. ANN.§ 141-H:4, 5 (1995). 
Il8. MINN. STAT.§ 72A.139(S) (1995). 
HeinOnline -- 7 Health Matrix 118 1997
118 HEALTH MATRIX [Vol. 7:97 
the statute specifically provides that "[i]f the individual tested 
has not given written consent authorizing a physician to receive 
the test results, the individual must be urged, at the time that 
the individual is informed of the genetic test results . . . to 
contact a genetic counselor or other health care profession-
al."n9 
As noted earlier, currently there is no federal law specifi-
cally addressing genetic privacy. It is critical that any federal 
legislation that regulates genetic (and medical) privacy not 
preempt stricter protections integrated into state anti-discrimi-
nation statutes. Furthermore, medical privacy legislation must 
specifically address protections of genetic information. Current-
ly, federal proposals are pending that vary with respect to how 
they address these issues.120 
Vll. RIGHTS AND RESPONSIDILITIES WITHIN 
THE FAMILY 
Concerns over privacy and confidentiality extend beyond 
the employment and insurance context. For many individuals, 
the primary concern may be for privacy in the context of fami-
ly, including the extended family. This is an area where it may 
be inappropriate for the law to have any meaningful role. Me-
diating roles based primarily on blood, rather than on family 
relationships, will create new challenges. In the Orthodox Jew-
ish community, there is fear that genetic testing without clear 
medical benefit will only cause harm to individuals, threaten 
the privacy of families, and even hamper the prospects of 
marriage. A Jewish Community Relations Council official 
queried, "If you know that someone in the family has a specif-
ic predisposition to BRCAl, what does this do [to] their possi-
ble matches?"121 
Traditional medical ethics may have to be re-examined to 
119. MINN. STAT. § 72A.l39(6) (1995). Similar provisions are included in the California 
slatute. See CAL. INS. CODE§ 10148(a)-(b) (Deering 1996). 
120. See S. 1360, 104th Cong. (1995) (proposing a bill entitled the "Medical Records 
Confidentiality Act of 1995"); S. 1898, 1 04th Con g. (1996) (proposing a bill entitled the "Genetic 
Confidentiality and Nondiscrimination Act of 1996"); H.R. 3482, 104th Cong. (19%) (proposing 
a bill entitled the "Medical Privacy in the Age of Technologies Act of 1996"). 
121. Doc Wants New Study of Jewish Cancer Gene, supra note 44, at 6. 
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accommodate changing rights and responsibilities within the 
family. The paradigm of individual autonomy in health care 
supports an individual's right to evaluate the benefits and risks 
of testing, to decide whether to be tested, and whether to share 
test results. However, in the context of genetics, what is the re-
sponsibility of the individual and the provider to share test 
results with other family members?122 Is the patient, in fact, 
the individual, or the family unit? When sharing information, 
how many generations should be included? Should a 
communitarian ethic of sharing be integrated into the ethical 
paradigm? What responsibilities will there be to obtain and 
share information about genetic predispositions to cancer? In 
certain cases, the mutation cannot be found without testing the 
affected carrier and other blood relatives. What if some rela-
tives want to be tested and some do not? Can family members 
keep genetic secrets? When should the researcher or physician 
intervene to encourage family members to participate in test-
ing? Who in the family should contact family members with 
genetic information? Although there is no ethical consensus or 
clear legal precedent in genetics, 123 in the context of HIV and 
communicable diseases, some conclude that one might have an 
ethical and legal duty to share information about contagious 
diseases.124 The rationale, in part, for the duty is to prevent 
122. See, e.g., Madison Powers, Privacy and the Control of Genetic Information, in THE 
GENETIC FROI'ITIER: ETHICS, LAw, AND POUCY 77,92-95 (MarkS. Frankel & Albert H. Teich 
eds., 1994) (discussing when genetic information should be disclosed to third parties in order to 
protect them from harm); Sonia M. Suter, Whose Genes are These Anyway? Familial Conflicts 
Over Access to Genetic Information, 91 MICH. L. REv. 1854, 1854 (1993) (arguing that courts and 
legislatures should not follow a presumption against mandating disclosure of a person's genetic 
information to third parties). 
123. See, e.g., Ruth Macklin, Privacy and Control of Genetic Information, in GENE 
MAPPING: USING LAW AND ETHICS AS GUIDES 157, 158 (George Annas & Shennan Elias eds., 
1992) (discussing the concept of privacy and its implication for the confidentiality of genetic 
information); Mary Z. Pelias, Duty to Disclose in Medical Genetics: A Legal Perspective 39 AM. 
J. MED. GENETics 347, 349-52 (1991) (discussing the duty of medical geneticists to disclose 
medical and genetic information in light of the lack of legal precedent governing a physician's 
duty to disclose). 
124. See, e.g., Kenneth E. Labowitz, Beyond Tarasoff: AIDS and the Obligation to Breach 
Confidentiality 9 ST. LoUISE U. PuB. L. REv. 495, 512 (1990) (discussing the medical 
profession's standard for third party notification concerning a patient who has a positive HIV 
status and the mandates of the Public Health Service and Center for Disease Control). But see, 
e.g., Karen H. Rothenberg & Stephen J. Paskey, The Risk of Domestic Violence and Women with 
HIV Infection: Implications for Partner Notification, Public Policy, and the Law, 85 AM. J. PUB. 
HEALTH 1569, 1569 (1995) (exploring implications of the partner notification strategy in the fight 
against AIDS in the context of domestic violence). 
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the spread of disease. Such an analogy may be premature and/-
or ill-advised in the context of predictive genetic testing for 
cancer. 
Two recent cases have considered the physician's duty to 
warn relatives that they are at risk of developing a genetic 
disease. In Pate v. Threlkel/ 25 the Florida Supreme Court 
analyzed the duty to warn the patient of "genetic transferabili-
ty" and the role of family members in sharing genetic informa-
tion.126 In this case, a patient's adult child brought a medical 
malpractice action based on the physicians' failure to warn the 
patient that her condition, medullary thyroid carcinoma, was 
genetically transferable and that her adult children should be 
tested for the condition.127 The court held that expert testi-
mony by physicians would determine the standard of care and 
thereby whether the physicians had a duty to warn under the 
circumstances. Obviously, this case demonstrates the impor-
tance of risk assessment, an understanding of cancer genetics, 
and the need for providers to take the lead, rather than the 
courts, in establishing the standard of care for genetic testing. 
The court also "emphasized" that in any circumstances in 
which the physician has a duty to warn of a genetically trans-
ferable disease, that duty will be satisfied by warning the pa-
tient."128 The court clarified that the physician has no duty to 
warn various members of the patient's family, reasoning that it 
would be prohibited by disclosure laws, as well as be impracti-
cal, difficult, and "place too heavy a burden on the physi-
cian."129 Rather, the court reasoned that the "patient ordinari-
ly can be expected to pass on the warning"130 to family mem-
bers. 
More recently, the New Jersey Superior Court, in Safer v. 
Pack,131 further expanded on the Pate opinion. In Safer, the 
plaintiff, who was diagnosed with a form of colon cancer, sued 
the estate of the physician who had first treated her father for 
125. 661 So.2d 278 (Fla. 1995). 
126. I d. at 280-82. 
127. See id. at 278-79. 
128. /d. at 282. 
129. /d. 
130. /d. 
131. 677 A.2d 1188 (NJ. 1996). 
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the same disease over forty years earlier. She argued that the 
physician had a duty to inform the family that they were poten-
tially at risk of developing this genetically transmissible condi-
tion. On appeal from the trial court's dismissal of her com-
plaint, the Superior Court held that the physician did have a 
duty to warn and declined to hold as in Pate "that in all cir-
cumstances, the duty to warn will be satisfied by informing the 
patient."132 It predicted that as the issues develop at trial, the 
court may have "to resolve a conflict between the physician's 
broader duty to warn and his fidelity to an expressed prefer-
ence of the patient that nothing be said to family members 
about the details of the disease."133 These two cases further 
highlight our need for better understanding family relation-
ships, privacy and confidentiality concerns, and realistic expec-
tations in the genetics context. 
In light of these developments, it may be even more criti-
cal to recognize the implications of testing children for cancer 
susceptibility.134 When, if at all, do you tell the child of their 
carrier status? Is it realistic to have a parent withhold such 
information from a child? If not, when is the right age to share 
this information? Considering the social and psychological 
risks associated with testing, it may only be appropriate for the 
child to make the decision to undergo testing when they reach 
maturity .135 If the testing of a child has a medical benefit that 
cannot be postponed until adulthood, it might be ethical to 
132. /d. at 1192. 
133. /d. 
134. See generally Board of Directors, Am. Soc'y of Hum. Genetics & Board of Directors, 
Am. C. of Medic. Genetics, Points to Consider: Ethical, Legal and Psychosocial Implications of 
Genetic Testing in Children and Adolescents, 57 AM. J. HUM. GENETICS 1233, 1234 (1995) 
(recommending that providers engage families in comprehensive discussions of genetic testing 
issues and provide them with specific information about testing) [hereinafter Am. Soc'y of Hum. 
Genetics & Am. C. of Medic. Genetics]; Ellen Wright Clayton, Removing the Shodow of the Law 
from the Debate about Genetic Testing of Children, 57 AM. J. MED. GENETICS 630, 630 (1995) 
(arguing that tort and constitutional law in the United States have limited impact in the debate 
over genetic testing of children); Diane E. Hoffmann & Eric A. Wulfsberg, Testing Children for 
Genetic Predispositions: Is it in Their Best Interest?, 23 J. L. MED. & ETHICS 331, 331 (1995) 
(exploring the psychological impact, burdens, benefits, and other issues associated with testing 
children for genetic predispositions); Dorothy C. Wertz et al., Genetic Testing for Children and 
Adolescents: Who Decides?, 272 JAMA 875, 875 (1994) (discussing the ethical, legal, and 
psychological implications of presymptomatic testing of children). 
135. See Am. Soc'y of Hum. Genetics & Am. C. of Med. Genetics, supra note 134, at 1238. 
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offer testing. 136 Because of concerns for psychological risk, 
stigma, and discrimination, parental anxiety alone should not 
be a justification for predictive testing of children.137 The Na-
tional Action Plan on Breast Cancer states that "[u]nless a 
benefit for medical interventions in childhood can be demon-
strated, which is currently not the case for heritable breast and 
ovarian cancer, testing on individuals younger than eighteen 
years should not be undertaken.'m8 
Reproductive decisionmaking in the genetic context also 
presents new and related challenges. In the near future, 
preimplantation diagnosis and assisted reproductive technolo-
gies may provide the wealthy with the option of the selective 
implantation of embryos with normal BRCAl genes. More 
generally, if genetic testing for cancer susceptibility is market-
ed to the general population, it may be targeted at pregnant 
women. A recent article in Obstetrics and Gynecology139 pre-
dicted that there would be increasing demand for prenatal 
testing for mutations in the BRCAl gen., 140 In fact, most ge-
netic testing is done on pregnant women141 and predictive 
testing for cancer may be no exception. 
More specifically, it is reasonable to predict that Jewish 
pregnant women will be the first group targeted since Jews are 
already being screened for other "Jewish" genetic disorders and 
are being recruited for 185delAG testing. 142 More generally, 
with knowledge of the mutation in the parent, prenatal testing 
using fetal cells will be relatively easy and quick, allowing for 
pregnancy termination.143 Will only female fetuses be tested 
and aborted? Is it ethical to abort for an adult onset disease in 
which we still understand so little about penetrance and the 
136. See id. at 1234. 
137. See id. at 1238. 
138. National Action Plan on Breast Cancer, Position Paper, Commentary on the ASCO 
Statement on Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL ONCOLOGY 1738, 1739 
(1996). 
139. Johnathan M. Lancaster et al., An Inevitable Dilemma: Prenatal Testing for Mutations 
in the BRCAJ Breast-Ovarian Cancer Susceptibility Gene, 87 OBSTETRICS & GYNECOLOGY 306, 
306 (1996). 
140. /d.at307. 
141. See, e.g., WOMEN AND PRENATAL TEsTING: FACING THE CHALLENGES OF GENETIC 
TECHNOLOGY (Karen H. Rothenberg & Elizabeth J. Thomson eds., 1994). 
142. See Genetics & IVF Institute, supra note 24. 
143. See Lancaster et al., supra note 139, at 307. 
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phenotypic effects of different mutations?144 Once the test is 
offered, we cannot place legal limits on termination options. 
Yet, if a woman decides not to abort, what implications does 
this have for the child's rights? We are in fact testing minors 
without their consent. The National Action Plan on Breast 
Cancer has determined that "[a] host of moral and ethical is-
sues make it inappropriate to offer testing for breast and ovari-
an cancer susceptibility as part of prenatal diagnosis."145 
Vlll. CONCLUSION: UNANSWERED QUESTIONS 
Predictive genetic testing for breast cancer raises a number 
of complex ethical, legal, and social challenges. Perhaps our 
greatest public policy challenge will be to determine when, if 
at all, it will be appropriate to make the transition from predic-
tive testing for high-risk individuals and families in a research 
context to testing the general population for cancer risk. Will 
the commercial market promote testing for the general popula-
tion before we have been able to carry out the benefit/risk 
analysis even in the high risk population?146 As the flow of 
genetic information increases, so too will the risk of its misuse. 
Should testing be restricted until we enact anti-discrimination 
144. See id. at 307. 
145. See National Action Plan on Breast Cancer, supra note 138, at 1739. 
146. See generally American Society of Clinical Oncology, Statement of the American 
Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL 
ONCOLOGY 1730, 1730-36 (1996) (stating that any physician who offers genetic testing should be 
aware of, and be able to communicate, the benefits and limits of current testing procedures, and 
the range of treatment options available to patients and their families); National Action Plan on 
Breast Cancer, supra note 138, at 1739 (stating that testing should only be done under institutional 
review board approved research studies); Frances M. Visco, National Breast Cancer Coalition, 
Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL 
ONCOLOGY 1737, 1737 (1996) (stating the National Breast Cancer Coalition's concern about the 
need for more research as well as the lack of legislation prohibiting the misuse of genetic 
information); National Advisory Council for Human Genome Research, Nat'I. Inst. of Health, 
Statement on Use of DNA Testing for Presymptomatic Identification of Cancer Risk, 271 JAMA 
785, 785 (1994) (discussing issues which must be addressed before widespread use of DNA 
testing for a predisposition to cancer can be recommended); Ad Hoc Committee on Breast and 
Ovarian Cancer Screening, Am. Soc. of Hum. Genetics, Statement of the American Society of 
Human Genetics on Genetic Testing for Breast and Ovarian Cancer Predisposition, 55 AM. J. 
HUM. GENETICS i (1994) (identifying characteristics and prerequisites for testing for the BRCA1 
cancer gene in high risk and general population groups). 
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and genetic privacy legislation nationwide? Should the com-
mercial market be regulated? How can we explain relative and 
absolute risks to the general public? How can we explain the 
limitations of testing technology? How can we assure quality 
control over the testing process? What implications will testing 
have, for example, on cancer surveillance and prevention strat-
egies within our current healthcare system? How will individu-
als be able to integrate predictive testing results with health 
behavior, lifestyle, and environmental factors that may signifi-
cantly contribute to cancer morbidity and mortality? How can 
the FDA and other regulatory agencies assure the public that 
predictive genetic testing has clinical and analytical validi-
ty?147 These questions have no simple answers. 
Thus, until we have a better understanding of the benefits 
and risks of genetic testing and our strategies for how best to 
proceed in order to protect the public, we must strive to resist 
a genetic "quick fix" mentality that promotes genetic testing in 
the healthcare market. Obviously, there is no "quick fix" for 
the ethical, legal, and social challenges. 
147. See Technological Advances in Genetic Testing: Implications for the Future, 104th 
Con g. 75-86 (1996) (statement of Karen H. Rothenberg). 
